Roberto Mercado-Longoría

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Impact of daily chlorhexidine baths and hand hygiene compliance on nosocomial infection rates in critically ill patients

Michel F. Martínez‐Reséndez, Elvira Garza‐González, Soraya Mendoza-Olazarán et al. · American Journal of Infection Control · 2014 · 49 citations

Healthcare-associated Infection, Patient Safety, Hand Hygiene Compliance +10

Carbapenemase-Encoding Genes and Colistin Resistance in Gram-Negative Bacteria During the COVID-19 Pandemic in Mexico: Results from the Invifar Network

Ulises Garza–Ramos, Jesús Silva-Sánchez, Luis Esaú López-Jácome et al. · Microbial Drug Resistance · 2023 · 29 citations

Eosinophil count at intensive care unit admission was not predictor of hospital mortality: results of a case control study

Emmanuel Escobar-Valdivia, Julio E. González-Aguirre, Eunice Rebeca Carrillo-Cisneros et al. · Journal of Intensive Care · 2015 · 17 citations · Full text

Disparities in cystic fibrosis survival in Mexico: Impact of socioeconomic status

Adriana Bustamante, Lucía T. Fernández, Lissette C. Rivas et al. · Pediatric Pulmonology · 2021 · 11 citations